Miguel Muniz, Charles L Loprinzi, Jacob J Orme, Regina M Koch, Ahmed M Mahmoud, Adam M Kase, Irbaz B Riaz, Jack R Andrews, Matthew P Thorpe, Geoffrey B Johnson, Ayse T Kendi, Eugene D Kwon, Jones T Nauseef, Alicia K Morgans, Oliver Sartor, Daniel S Childs
Clinical trials of prostate-specific membrane antigen (PSMA) targeted radiopharmaceuticals have shown encouraging results. Some agents, like lutetium-177 [177Lu]Lu-PSMA-617 ([177 Lu]Lu-PSMA-617), are already approved for late line treatment of metastatic castration-resistant prostate cancer (mCRPC). Projections are for continued growth of this treatment modality; [177 Lu]Lu-PSMA-617 is being studied both in earlier stages of disease and in combination with other anti-cancer therapies. Further, the drug development pipeline is deep with variations of PSMA-targeting radionuclides, including higher energy alpha particles conjugated to PSMA-honing vectors...
April 30, 2024: Cancer Treatment Reviews